III 

118TH CONGRESS 

2D SESSION S. RES. 735 

Designating July 17, 2024, as ‘‘Glioblastoma Awareness Day’’. 

IN THE SENATE OF THE UNITED STATES 

JUNE 13, 2024 

Mr. GRAHAM (for himself, Ms. SINEMA, Mr. SCOTT of South Carolina, Mr. 

KELLY, Mr. VAN HOLLEN, Mr. WARNOCK, Mr. RUBIO, Mr. MARKEY, Ms. 

WARREN, Mr. COONS, and Mr. BARRASSO) submitted the following resolution; which was considered and agreed to 

RESOLUTION 

Designating July 17, 2024, as ‘‘Glioblastoma Awareness 

Day’’. 

Whereas approximately 14,490 new cases of glioblastoma 

were diagnosed in the United States in 2023; 

Whereas glioblastoma is— 

(1) the most common malignant (cancerous) brain 

tumor, accounting for approximately 1⁄2 of all primary 

malignant brain tumors; and 

(2) the most aggressive, complex, difficult to treat, 

and deadly type of brain tumor; 

Whereas it is estimated that more than 10,000 individuals in 

the United States will succumb to glioblastoma each year; 


ssavage on LAPJG3WLY3PROD with BILLS
2 

•SRES 735 ATS 

Whereas the 5-year survival rate for glioblastoma patients is 

only 6.9 percent, and the median length of survival for 

glioblastoma patients is only 8 months; 

Whereas glioblastoma is described as a disease that affects 

the ‘‘essence of self’’, as the treatment and removal of 

glioblastoma presents significant challenges due to the 

uniquely complex and fragile nature of the brain, the primary organ in the human body that controls not only 

cognitive ability, but also the actions of every organ and 

limb; 

Whereas patients and caregivers play a critical role in furthering research for glioblastoma; 

Whereas, relative to the patients of other types of cancers, 

brain cancer patients pay the second highest out-of-pocket costs for medical services in both the initial and endof-life phases of care; 

Whereas, although research advances may fuel the development of new treatments for glioblastoma, challenging obstacles to accelerating progress toward new treatments 

for glioblastoma remain, and there are no screening or 

early detection methods; 

Whereas, in 2021, the World Health Organization reclassified 

brain tumors and made significant changes to the molecular characteristics of a glioblastoma diagnosis, necessitating critical biomarker testing for patients suspected of 

having glioblastoma; 

Whereas, although glioblastoma was first described in medical 

and scientific literature in the 1920s, and despite its devastating prognosis, only 5 drugs and 1 medical device 

have been approved by the Food and Drug Administration to specifically treat glioblastoma since the 1920s, 


ssavage on LAPJG3WLY3PROD with BILLS
3 

•SRES 735 ATS 

and the mortality rates associated with glioblastoma have 

changed little during the past 30 years; 

Whereas, since the first Glioblastoma Awareness Day, the 

National Cancer Institute established the Glioblastoma 

Therapeutics Network in 2020, a network of multi-institutional teams that enhance and support the discovery 

and development of glioblastoma therapies by driving 

therapeutic agents through pre-clinical studies and earlyphase clinical trials, which are necessary to rapidly evaluate potential treatments to advance toward cures and improved quality of life; and 

Whereas there is a need for greater public awareness of glioblastoma, including awareness of both— 

(1) the urgent unmet medical needs of glioblastoma 

patients; and 

(2) the opportunities for research of, and treatment 

advances for, glioblastoma: Now, therefore, be it 

1 Resolved, That the Senate— 

2 (1) designates July 17, 2024, as ‘‘Glioblastoma 

3 Awareness Day’’; 

4 (2) encourages increased public awareness of 

5 glioblastoma; 

6 (3) honors the individuals who have died from 

7 the devastating disease of glioblastoma or are cur8 rently living with the disease; 

9 (4) supports efforts to develop better treat10 ments for glioblastoma that will improve the long11 term prognosis for, and the quality of life of, individ12 uals diagnosed with the disease; 


ssavage on LAPJG3WLY3PROD with BILLS
4 

•SRES 735 ATS 

1 (5) recognizes the importance of molecular bio2 marker testing to the diagnosis and treatment of 

3 glioblastoma; 

4 (6) expresses support for the individuals who 

5 are battling brain tumors, as well as the families, 

6 friends, and caregivers of those individuals; 

7 (7) urges a collaborative approach to brain 

8 tumor research among governmental, private, and 

9 nonprofit organizations, which is a promising means 

10 of advancing the understanding and treatment of 

11 glioblastoma; and 

12 (8) encourages continued investments in glio13 blastoma research and treatments, including through 

14 the Glioblastoma Therapeutics Network and other 

15 existing brain tumor research resources. 

Æ 


ssavage on LAPJG3WLY3PROD with BILLS